Trials / Completed
CompletedNCT06466369
Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia
Efficacy and Safety of Once Daily Administration Tadalafil in Patients With Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Al-Azhar University · Academic / Other
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil | tadalafil 2.5 mg, 5 mg |
Timeline
- Start date
- 2024-03-15
- Primary completion
- 2024-07-01
- Completion
- 2024-08-01
- First posted
- 2024-06-20
- Last updated
- 2024-08-23
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06466369. Inclusion in this directory is not an endorsement.